Q3 2020 Sales Performance

Consumer Healthcare Q3 2020 Sales gsk Operating margin Sales All figures £m Continuing +3% CER Total -6% CER + VMS consumer usage -90bps CER 2,733 24.2% (+) Sensodyne strength 2,526 2,422 24.3% 709 22.3% 709 702 581 526 + Voltaren OTC switch in US Reversal of Q2 stocking following systems cutover Impact of divested brands 537 357 662 613 344 294 541 318 224 353 425 461 456 298 307 80 Q319 Q319 Q320 Q319 Reported Q319 Pro-forma Q320 Reported Pro-forma Operating profit + Synergy delivery and cost control Impact of divested brands Brand investment Oral health VMS Pain relief Digestive health and other Respiratory health Brands divested/under review 91

View entire presentation